What do systematic reviews say?

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 194 participants
  Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 89 participants
  Low

Pulmonary rehabilitation plus inspiratory muscle training vs pulmonary rehabilitation alone

• Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 908 participants
  Low
• Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 657 participants
  Very low

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

The review found no eligible studies for this question.

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 238 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 478 participants
  Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 240 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 163 participants
  GRADE not reported

Pulmonary rehabilitation vs usual care

• Pulmonary rehabilitation versus usual care for adults with asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 442 participants
  Very low

Pulmonary rehabilitation vs usual care

• Pulmonary rehabilitation versus usual care for adults with asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 440 participants
  Moderate

Pulmonary rehabilitation vs usual care

• Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1003 participants
  High

PPI plus usual care vs usual care alone or chronic obstructive pulmonary disease

The review found no eligible studies for this question.

• Proton pump inhibitors for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ immunostimulant vs placebo

• Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 617 participants
  Very low

Remote monitoring vs usual care

The review found no eligible studies for this question.

• Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Multi‐component interventions (with telehealth as a component of care) vs usual care

The review found no eligible studies for this question.

• Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Remote monitoring plus usual care vs usual care

The review found no eligible studies for this question.

• Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found